As of November 6, 2026, Citius Oncology, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 12, 2026 (Form 8-K, August 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Citius Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Citius Oncology, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-12. Every row below is cited to the filing it comes from, and this page adds each new change as Citius Oncology, Inc. files it.
Also on the record for Citius Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| June 4, 2026 | Stake report, Schedule 13D/A, by Citius Pharmaceuticals, Inc. | 71% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| December 17, 2025 | Stake report, Schedule 13D/A, by Citius Pharmaceuticals, Inc. | 77.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.79% of the class | 5%+ stakes | Source |
| September 12, 2025 | Stake report, Schedule 13D/A, by Citius Pharmaceuticals, Inc. | 79.1% of the class | 5%+ stakes | Source |
| July 25, 2025 | Stake report, Schedule 13D/A, by Citius Pharmaceuticals, Inc. | 84.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Citius Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Citius Oncology, Inc. and the records around it.
Citius Oncology, Inc. elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Citius Oncology, Inc.
Get an email when Citius Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Citius Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Citius Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Citius Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-12 | Reported | not named in the filing | 8-K, 2026-08-12 |
New leaders reset buying decisions — get the Full Report on Citius Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Citius Oncology, Inc., with the record behind each one.
Find candidates like senior executive at Citius Oncology, Inc.Every change, in the filing's words
Reported
After conducting a broad and thorough process, the Corporate Governance and Nominating Committee recommended Dr. Peri for appointment to the Board.
- (d) On August 7, 2026, the Board of Directors (the "Board") of Citius Oncology, Inc. (the "Company") expanded the number of directors serving on the Board to nine individuals and appointed Jonathan Peri, Ph.D., J.D. as a Class I member of the Board, effective August 10, 2026, to serve until the Company's 2028 annual meeting of stockholders or until his successor is duly elected and qualified.
- While the Board's Corporate Governance and Nominating Committee has not formulated any specific minimum qualifications for director candidates, it has determined certain desirable characteristics including strength of character, mature judgment, career specialization, relevant technical skills, and independence.
- The Board has determined that Dr. Peri is an independent director under the relevant SEC and Nasdaq Stock Market listing rules.
- Following Dr. Peri's appointment, the Board remains majority independent.
- Dr. Peri will be compensated in accordance with the Company's compensation program for independent directors, which is currently undergoing review by the Board.
- Dr. Peri, 52, has served as President of Manor College since October 2015.
- He has served as an elected Commissioner of Middle States Commission on Higher Education (MSCHE), a premier university accrediting agency since July 2019 and was appointed Vice Chair in July 2026.
Tools for this story
Each opens in a new tab, filled in for Citius Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.